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Activation represents a significant bioenergetic challenge for T-cells, which must undergo
metabolic reprogramming to keep pace with increased energetic demands. This review
focuses on the role of fatty acid metabolism, both in vitro and in vivo, following T-cell acti-
vation. Based upon previous studies in the literature, as well as accumulating evidence
in allogeneic cells, I propose a multi-step model of in vivo metabolic reprogramming. In
this model, a primary determinant of metabolic phenotype is the ubiquity and duration
of antigen exposure. The implications of this model, as well as the future challenges and
opportunities in studying T-cell metabolism, will be discussed.
Keywords: T-cell metabolism, fatty acid oxidation, oxidative phosphorylation, reactive oxygen species (ROS),
AMP-activated protein kinase, graft-versus-host disease, in vivo models
INTRODUCTION
Activation precipitates a dramatic change in T-cell physiol-
ogy. Upon stimulation, T-cells increase their DNA replication,
synthesize cytokines, and upregulate multiple signaling path-
ways (1, 2). Proliferation increases exponentially, with stimulated
cells dividing as frequently as every 4–6 h at the height of an
immune response (3, 4). The energetic requirements for these
new tasks dictate that T-cells must undergo metabolic repro-
graming in order to generate sufficient biomass and produce
adequate adenosine triphosphate to meet the increased metabolic
demands (5).
In recent years, increasing attention has focused on the meta-
bolic pathways adopted by T-cells following activation. Many fine
contemporary reviews highlight the relationship between meta-
bolic phenotype and signal transduction (6, 7), T-cell differenti-
ation (8, 9), and T-cell function (5, 10). Other reviews stand as
thorough summaries on overall T-cell metabolism, and the reader
is encouraged to seek out these important works (11). This review
will focus on the use of fatty acid oxidation (FAO) by activated T-
cells, both in vitro and in vivo, and suggest a possible connection
between the environment present during activation and adoption
of this alternative metabolic pathway. To place the findings on FAO
into a contextual framework, I will begin by briefly reviewing the
role of other metabolites, including glucose and amino acids, in
T-cell metabolism.
THE NECESSITY OF GLYCOLYSIS AND AMINO ACIDS
Early studies demonstrated increased rates of both glycolysis
and lactate production during mitogen activation of rat thy-
mocytes, suggesting a prominent role for glucose metabolism
during in vitro T-cell stimulation (12). Following activation, T-
cells increase multiple steps in glucose metabolism, including
upregulation of the glucose transporter Glut1, in a highly regu-
lated process that is at least partially dependent upon signaling
through the co-stimulatory molecule CD28 (13–15). Failure of
T-cells to sufficiently increase glucose metabolism decreases both
proliferation and cytokine production, while overexpression of
a transgenic Glut1 receptor increases cytokine production and
improves T-cell survival (16, 17).
Glutamine metabolism is also requisite during T-cell activation
and limiting glutamine in the culture media decreases prolifera-
tion and cytokine production in mitogen-stimulated lymphocytes
(18). Studies on purified populations of T-cells confirmed the
importance of glutamine uptake during in vitro stimulation and
implicated a role for CD28 in maximizing glutamine uptake (19).
In addition, inflammatory CD4 T-cell responses depend on glu-
tamine uptake through expression of the amino acid transporter
Slc1a5 (20), and absence of Slc1a5 decreases the percentage of
IFN-γ+ T-cells responding to Listeria monocytogenes infection.
Similarly, the transcription factor Myc plays a pivotal role in direct-
ing glutamine into obligate biosynthetic pathways and facilitates
the initial proliferative burst (21). Thus, both glucose and glut-
amine appear indispensable for early events in T-cell metabolic
reprograming.
In addition to glutamine, T-cells require access to other amino
acids for proliferation and survival. Expression of the bidirec-
tional glutamine/leucine transporter Slc7a5 is an integral event
in early T-cell activation and absence of this receptor decreases
T-cell responses both in vivo and in vitro (22). The importance
of this receptor is intriguing, given that leucine is a necessary
component of T-cell activation and that higher glutamine levels
facilitate leucine import through simultaneous glutamine export
(23). Therefore, a large role for glutamine may simply be to pro-
vide an intracellular gradient to support transport of other amino
acids. This hypothesis is supported by the finding that glutamine
transporter deficiency can be overcome through increasing con-
centrations of leucine. Additional data suggest that glutamine
transport may even initiate metabolic adaptation, as absence of
Slc1a5 in T-cells blunts expression of other metabolic mediators
including both Glut1 and CD71 (22).
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In addition to leucine, T-cells also depend upon tryptophan
to execute full effector function. Suppressed T-cell responses are
observed when antigen presenting cells contain indolamine 2,3-
dioxygenase (IDO), an enzyme that catabolizes tryptophan (24,
25). The importance of the IDO pathway has been demon-
strated in multiple immunogenic processes, including fetal toler-
ance during pregnancy, bone marrow transplantation, antitumor
responses, and autoimmunity (26). In addition, kynurenine, a
tryptophan catabolite, induces regulatory T-cell generation (Treg)
through its action on the aryl-hydrocarbon receptor (21). Thus,
T-cell responses can be modulated by both decreased levels of a
nutrient (tryptophan) and the actions of its metabolic derivative
(kynurenine).
NUTRIENT REGULATION OF T-CELL DIFFERENTIATION
Other nutrients also influence T-cell differentiation and func-
tion. Short-chain fatty acids, such as propionate and butyrate,
are generated via fermentation by intestinal bacteria and intestinal
levels of these fatty acids also modulate Treg formation (19, 27,
28). Similar to kynurenine, propionate and butyrate likely drive
Treg formation through specific intestinal T-cell nutrient recep-
tors, but the precise mechanism has yet to be confirmed. In a
similar way, Vα9+Vδ2+ gamma-delta T-cells selectively respond
to the microbial metabolite (E)-4-hydorxy-3-methyl-but-2-enyl
pyrophosphate (29). High salt concentrations also affect T-cell
function and drive CD4 T-cells toward a Th17 phenotype both
in vivo and in vitro. This is clinically relevant because dietary
increases in salt worsen the severity of experimental autoimmune
encephalomyelitis in murine models (30, 31). Salt sensitivity in
Th17 cells occurs via increased expression of serum glucocorticoid
receptor-1, a protein, which governs sodium homeostasis in multi-
ple cell types (32). Thus, extracellular nutrients not only help meet
increased energy needs of activated T-cells, but may also dictate
their differentiation and effector status.
THE ROLE OF FATTY ACID OXIDATION
Oxidation of fat, in addition to the catabolism of glucose and glu-
tamine, was first implicated as an energy source in unstimulated
lymphocytes (33), although most studies suggest that naïve T-cells
require only a minimal rate of metabolism to meet their bioen-
ergetics needs (5, 34). A role for FAO in other subsets first came
from work in T-cells bearing a deletion of TNF receptor associ-
ated factor 6 (TRAF6). CD8 T-cells deficient in TRAF6 are unable
to form memory cells in response to infection with L. monocyto-
genes and when taken ex vivo, decrease rates of β-oxidation (35).
Furthermore, indirect activation of AMP-activated protein kinase
(AMPK), a cellular energy sensor and controller of FAO (36–38),
increased CD8 memory T-cell generation and improved survival in
a lethal tumor model. Subsequent in vitro work demonstrated that
IL-15, an important cytokine in memory T-cell generation, upreg-
ulates expression of carnitinepalmitoyltransferase 1a (CPT1a), the
rate limiting enzyme in FAO (39). These studies suggest a subset
specific role for FAO in the generation of CD8 memory T-cells.
CD4 T-cells cultured in vitro also exhibit a subset specific
dependence on FAO. T-cells differentiated in vitro toward Th1,
Th2, or Th17 profiles adopt a glycolytic phenotype, consistent
with earlier findings on T-cell metabolism (13, 14). In contrast,
Tregs generated in vitro increase lipid oxidation and phosphory-
late AMPK. Furthermore, in vitro blockade of FAO with the CPT1a
inhibitor etomoxir disrupts Treg generation and in vitro supple-
mentation with fatty acids supports Treg function (17). In vivo
administration of metformin increases both the percentage and
total number of Treg during a murine model of asthma (17).
Together, these data support a mandatory role for FAO in both
IL-15 driven CD8 T-cell responses and in the induction of in vitro
generated Tregs. Furthermore, metformin administration, which
indirectly activates AMPK, increases both Treg and memory CD8
T-cells, and could indicate a role for AMPK in controlling FAO in
these cell types (17, 35). This notion is supported by the fact that
CD8 T-cells deficient in AMPKα1 mount inferior memory T-cell
responses following L. monocytogenes infection (40). It remains
unclear, however, exactly how metformin increases Treg and CD8
memory T-cells and the extent to which AMPK controls pathways
of T-cell metabolism beyond FAO (41–43).
Metformin is a direct inhibitor of Complex I of the electron
transport chain (44) and through inhibition of oxidative phos-
phorylation can indirectly accelerate glycolysis (45). However, it is
unlikely that increased glycolysis drives memory T-cell formation,
as glycolytic inhibition has already been shown to increase CD8
memory T-cell generation (46). However, the rapid recall response
of memory T-cells requires an imprinted glycolytic potential (47),
suggesting that the transition from memory to effector phenotype
depends upon glycolysis and is, therefore, potentially influenced
by the indirect effects downstream of metformin. Further clarity
on the direct role of AMPK in driving FAO and will be gained
using more selective inhibitors of AMPK and genetically deficient
animal models (43, 48).
One of the key challenges in studying immune cell metabolism
in vitro is the relevance of experimental systems to the environ-
mental conditions encountered in vivo (10, 49). Standard culture
concentrations differ greatly from physiologic values, including
higher concentrations of glucose (three- to fivefold higher than
the standard serum glucose of 5 mM), glutamine (eightfold higher
than serum levels), and oxygen (21% in culture compared to 2–5%
in vivo) (50). Changes in these environmental variables can affect
both a cell’s function and metabolic response (51). For example,
decreased glucose availability modulates both oxygen consump-
tion and metabolic transcription factors during human CD4 T-cell
activation (52). Hypoxia reduces proliferation and cytokine pro-
duction and promotes glycolysis (53, 54). Thus, the metabolic
phenotype adopted by a T-cell following in vitro stimulation may
be very different from the phenotype adopted by T-cells activated
under physiologic conditions in vivo (55).
One attractive approach to this challenge is to study meta-
bolic reprograming in lymphocytes activated in vivo during graft-
versus-host disease (GVHD). During GVHD, alloreactive donor
T-cells respond robustly to the presence of host antigens, leading
to marked proliferation, destruction of host tissues, and profound
inflammation (56–58). Allogeneic T-cells taken directly from
GVHD animals demonstrate a 2.5-fold increase in oxygen con-
sumption (a surrogate for oxidative phosphorylation) and a mod-
est increase in the expression of Glut1 (59). Increased oxidative
metabolism during GVHD is consistent with data from patients
with systemic lupus erythematosus, where isolated T-cells increase
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their mitochondrial mass by 50% and expand their mitochondrial
membrane potential by 20%. Similarly, peripheral blood mononu-
clear cells from these patients increase oxygen consumption by
50% compared to healthy control cells (60, 61).
Recent studies suggest a direct role for FAO in effector T-cells
during GVHD. Levels of acylcarnitines, necessary intermediates
in the oxidation of fat (62), increase 10-fold or more in allo-
geneic T-cells by day 7 post-transplant (59). In addition, effector
GVHD T-cells (characterized by their CD44hi, CD62Lo pheno-
type) increase fatty acid transport, upregulate levels of CPT1a and
CPT2, and increase their rates of FAO ex vivo (63). Treatment
of allogeneic cells with etomoxir selectively decreases their prolif-
eration in vitro, while etomoxir administration in vivo decreases
both total donor T-cell numbers and the severity of GVHD (63).
In contrast, T-cells proliferating in a homeostatic fashion after
transplantation, and those responding to cellular immunization,
minimally increase fatty acid transport and display no sensitivity
to etomoxir (63). Thus, FAO appears to be a specific metabolic
adaptation in effector T-cells proliferating in response to large
quantities of antigen. This is supported by findings in an exper-
imental autoimmune encephalomyelitis model, where etomoxir
blockade of FAO decreased disease severity, limited demyelination,
and reduced effector cytokine production (64).
Consistent with an increase in oxidative phosphorylation, allo-
geneic T-cells also increase generation of reactive oxygen species
(ROS) (59). Increased ROS likely result from increased mitochon-
drial membrane potential (∆ψm), which prolongs the half-life
of reactive intermediates in the electron transport chain, leading
to increased leak of single electrons from the intra-mitochondrial
space and subsequent formation of ROS (65). The increased ROS
observed in allogeneic T-cells is also consistent with data from
patients with systemic lupus erythematosus, where T-cells exhibit
both hyperpolarization of the ∆ψm and increased ROS (61). In
addition, increases in ROS and oxidative phosphorylation can
be therapeutically targeted, as modulators of complex V of the
electron transport chain mitigate the severity of GVHD without
affecting homeostatic reconstitution (59).
The increased glycolysis in T-cells during GVHD is modest
compared to the level of glycolysis and glucose uptake observed
during in vitro activation (14, 55). Calculations based upon O2
consumption suggest a larger contribution from oxidative metab-
olism toward total energy production in allogeneic T-cells (66).
This disparity might be accounted for by differences between
in vitro and in vivo conditions, as described earlier (52). However,
this explanation fails to account for situations where in vivo effec-
tor T-cells do not upregulate fatty acid transport following cellular
immunization or increase mitochondrial mass following infection,
as might be expected from cells with increased oxidative metabo-
lism (39, 63). To unify the disparate results both between in vitro
and in vivo conditions, and across different in vivo scenarios, I
propose a multi-step model of metabolic reprograming in T-cells
(Figure 1), where a primary determinant of metabolic pheno-
type is both the duration and degree of environmental stimulation
present at the time of analysis.
In setting up this model, it is important to note that T-cells
during GVHD do not increase fatty acid transport until their fifth
division, which occurs on approximately day 3 post-transplant
FIGURE 1 | A multi-step model of in vivo metabolic reprograming. Early
in a graft-versus-host (GVH) response, T-cells use glycolysis, glutaminolysis
and glucose oxidation to meet their short term energy needs (16, 21, 67).
By day 3 post-transplant, robustly activated cells (shown in red) require
additional metabolic reprograming to keep pace with ongoing energetic
demands and so upregulate fatty acid oxidation (FAO) by increasing fat
uptake, turning on co-activator molecules, and upregulating fatty acid
oxidation enzymes. This transition comes with a concomitant rise in
reactive oxygen species and a moderation in the rate of glycolysis (63, 68).
In contrast, T-cells stimulated via cellular immunization, with a limited
duration of antigen exposure, only transiently increase fat uptake and ROS
on day 3. As antigen levels fall, stimulation decreases and cells no longer
require FAO (cells shown in blue). Levels of oxidation enzymes, co-activator
molecules, fat transport, and ROS levels decrease to baseline in these cells
(63). Thus, despite similar CD44HiCD62LLo effector profiles, the metabolic
phenotype on day 7 is clearly different between robustly and transiently
activated T-cells. From these data, I propose that a primary determinant of
metabolic reprograming in effector T-cells is both the degree and duration
(< or >3 days) of antigen exposure at the time of evaluation.
(63). Thus, early events in T-cell activation, even in the presence
of significant antigen, do not require additional fatty acids. Instead,
early during a graft-versus-host (GVH) response, T-cells likely uti-
lize glycolysis and glutaminolysis to meet their short-term energy
needs (16, 21). This idea is supported by data obtained following
in vivo administration of the superantigen staphylococcal entero-
toxin B (SEB), where SEB sensitive CD4+, Vβ8+ cells undergo a
15-fold increase in glycolysis 48 h post-administration of SEB (21).
Initial dependence on glycolysis also explains the early in vivo sen-
sitivity of T-cells to the glycolysis inhibitor 2-deoxyglucose (67).
Later in the response (i.e., after 4–5 cell divisions), robustly acti-
vated T-cells require additional reprograming to keep pace with
the ongoing demands of persistent activation (68). This repro-
graming includes increased fatty acid uptake, upregulation of
oxidation enzymes and co-activator molecules, moderation in the
rate of glycolysis, and adoption of FAO with a concomitant rise
in ROS. This view is consistent with effector T-cells maintaining
oxidative phosphorylation following activation under a variety of
activating conditions (21, 39, 69). Mechanisms that drive this sec-
ond metabolic transition remain undefined, but signaling through
PD-1 is known to restrict glycolysis (70). In addition, AMPK pro-
motes FAO in multiple systems and is known for its ability to
act as a “cellular energy sensor” (36, 37, 71, 72). Indeed, knock-
out of AMPKα1 increases Glut1 expression, hexokinase levels,
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and glycolytic metabolism in purified T-cells. These observations
suggest that when present, AMPK might actively dampen T-cell
glycolysis (73), perhaps at the cost of promoting FAO (Figure 2).
Implicit in the multi-step model is the idea that continued
stimulation of the T-cell receptor (TCR) drives later stages of meta-
bolic reprograming. As antigen levels fall during the resolution of
an immune response, stimulation decreases, energetic demands
shrink, and effector T-cells no longer require utilization of alter-
native energy sources. Transgenic OT-I T-cells, when transferred
into irradiated recipients that bear ovalbumin as a self-protein,
markedly increase fat transport, ROS levels, and markers of oxida-
tive metabolism. In contrast, when the same OT-I T-cells are stim-
ulated by immunization with OVA-bearing dendritic cells, they
return to baseline values of fat transport and oxidative metabo-
lism by day 6 post-immunization (63). In these models, differences
between GVHD and immunization responses were not dependent
on differentiation status of the responding OT-I cells. Cells from
either environment had similar CD44HiCD62Lo profiles and made
equivalent amounts of IFN-gamma upon re-stimulation, consis-
tent with the ability to separate effector function and metabolic
phenotype on a per cell basis (74).
Although allogeneic T-cells only modestly increase glycolysis
(59), glucose is still likely being utilized by these cells in alternative
pathways. Indeed, shunting of glucose through the pentose phos-
phate pathway increases levels of reducing equivalents through
production of NADPH and also generates building blocks for
nucleic acid synthesis (75). In addition, glucose derivatives can
be combined with oxaloacetate in the TCA cycle to form citrate,
exported back to the cytosol via the carnitine/palmitate shuttle,
converted into acetyl-CoA and then malonyl-CoA via the action
of acetyl-CoA carboxylase 1 (ACC1), and eventually incorpo-
rated into de novo lipid synthesis. Evidence that a similar process
FIGURE 2 | Potential drivers of fatty acid oxidation. Mechanisms that
drive transition of robustly activated T-cells toward oxidative metabolism and
fatty acid oxidation remain undefined. The checkpoint molecule PD-1 is
upregulated early on allogeneic T-cells and PD-1 expression tracks with
levels of reactive oxygen species during GVHD (manuscript in preparation).
In addition, signaling through PD-1 is known to restrict T-cell glycolysis (70).
AMPK acts as a “cellular energy sensor” and may respond to increasing
AMP/ATP ratios as cells proliferate beyond 4–5 cell divisions. AMPK
promotes oxidative metabolism (OxPhos) and FAO in multiple systems (36,
37, 71, 72) and knockout of AMPKα1 increases glycolytic metabolism in
T-cells (73). Thus, activated AMPK might simultaneously dampen T-cell
glycolysis while promoting adoption of FAO during periods of persistent
antigen activation.
occurs in activated T-cells comes from work using ACC1 defi-
cient T-cells. CD8 T-cells lacking ACC1 have impaired survival
following L. monocytogenes infection (74) and ACC1 deficiency
preferentially disrupts in vitro differentiation of Th17 T-cells while
simultaneously sparing development of Treg (76). This Th17/Treg
dichotomy is reminiscent of studies on hypoxia-inducible factor
1-α and aryl-hydrocarbon receptor signaling, where promotion of
Th17 responses occurs at the expense of Treg generation (77, 78).
In addition, both treatment with an ACC1 specific inhibitor and
use of ACC1 deficient T-cells leads to diminished severity of EAE
(76). However, in contrast to FAO inhibition, which preferentially
affects antigen-activated T-cells (63), deficiency of ACC1 impacts
both antigen-activated and homeostatic responses (74). This sug-
gests that lipid synthesis, as driven by ACC1, is likely a necessity
for proliferation of all T-cells.
Similar to the diversity of glucose metabolism, glutamine may,
in addition to glutaminolysis, play a role as a metabolic substrate in
one-carbon serine metabolism, as has been shown for proliferating
cancer cells (79). Thus, as effector T-cells proliferate beyond 4–5
cell divisions with ongoing TCR stimulation, the roles of glucose
and glutamine likely change, as increased fat transport feeds fatty
acids into the TCA cycle. However, even fat-derived intermediates
may exit the TCA cycle into alternative metabolic shunts (e.g., via
the aspartate-malate shuttle) and the role of these divergent path-
ways during the latter stages of ongoing T-cell activation remain
exciting areas for future investigation.
Given the ability of effector T-cells to reprogram their meta-
bolic phenotype, the question arises as to whether T-cells can be
pre-programed for the physiologic conditions they will encounter
in vivo, a potential advantage when providing anti-viral or anti-
tumor immunity. Recent work lends credence to this possibility.
Treatment of ex vivo CD8 T-cells with the glycolysis inhibitor 2-
deoxyglucose (2DG) increases phosphorylation of AMPK, height-
ens oxygen consumption, and decreases multiple markers of
glycolysis in these cells. In addition, ex vivo treatment of cells
with 2DG enhances their in vivo antitumor function (46). These
data suggest that glycolytic inhibition ex vivo drives upregula-
tion of alternative metabolic phenotypes, which then provide a
subsequent selective survival advantage in vivo.
In contrast to allogeneic activation, T-cells responding via
homeostatic proliferation minimally upregulate fatty acid trans-
port and are not susceptible to FAO inhibition. This observation
suggests that the metabolic demands of homeostatic renewal are
distinct from those of T-cell activation, as has been seen in other
studies of T-cell metabolism (22). These results also imply that
modulating T-cell metabolism may offer a selective intervention
against pathogenic cells, potentially leading to a decrease in overall
immunosuppression (55, 59). From this perspective, it becomes
critically important to understand at which stage of metabolic
reprograming the intervention occurs. Some therapies, such as
antithymocyte globulin, will eliminate all T-cells regardless of pro-
liferation or activation status. Other treatments, like inhibition of
ACC1, will affect survival of all proliferating T-cells, regardless
of the stimulus (antigen-activated versus homeostatic cues) (74).
Interventions that disrupt early events in TCR-activated metabolic
reprograming (e.g., disruption of amino acid transport) might
spare homeostatic T-cells, but will target T-cells whose metabolic
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reprograming is driven through TCR stimulation (80). Finally,
interventions that affect the latter stages of metabolic adaptation,
such as inhibition of FAO or modulation of oxidative phosphory-
lation, will likely only inhibit effector T-cells responding to pro-
longed antigenic stimulus (63). This last form of intervention may
be particularly relevant in T-cells undergoing continuous exposure
to antigen (e.g., during autoimmunity and following transplanta-
tion of bone marrow or solid organs) and highlights situations
that will gain the most from selective immunotherapy, as cur-
rent immunosuppression for these disorders leads to significant
morbidity and mortality (81–84).
CHALLENGES FOR THE FUTURE
The rapid increase in our understanding of T-cell metabolism
offers exciting opportunities and presents several challenges. The
majority of initial metabolic studies were performed in vitro and
many of these paradigms and results may not reflect in vivo bio-
logic reality, which needs to be addressed. In addition, metabolic
adaptation is by necessity a dynamic and responsive process, and
conditions both inside and outside the T-cell change dramatically
from one moment to the next. Thus, a thorough view of metab-
olism in any model needs to incorporate data and observations
from multiple time points of analysis. Third, we know very little
about the molecular machinery that drives adoption of metabolic
phenotypes, particularly in vivo. Follow-up studies will need to
not only identify proteins important in T-cell metabolism, but
also define how the dependence on these factors changes during
the course of an immune response. The field also needs meta-
bolic activators and inhibitors with increased specificity, both for
study purposes and the potential for therapeutic intervention (43).
Finally, the study of T-cell metabolism needs to expand to better
include the human immune system, particularly in the context
of immune-mediated disorders. Future studies in human beings
will benefit both from clinically based flux analysis using labeled
metabolites such as 13C-glucose or 13C-palmitate (85, 86) and the
great variety of pathways and compounds being discovered in the
field of cancer therapy (79, 87–90).
CONCLUSION
T-cell activation represents a time of significant energetic stress
and cells must respond to this challenge by reprograming their
metabolism to keep pace with increased metabolic demands. Dur-
ing a murine model of GVHD,effector T-cells increase their depen-
dence on oxidative metabolism and FAO. Adoption of these path-
ways is likely due to environmental factors present at the time of
T-cell recovery and analysis, including the ubiquity and duration
of antigen exposure. Thus, T-cell differentiation status (e.g., mem-
ory versus effector) is not the sole arbitrator of metabolic pheno-
type, and our data suggest that effector T-cells will instead respond
as necessary to meet the metabolic demands placed upon them,
including upregulation of FAO. Future studies will determine how
broadly findings on allogeneic T-cells can be applied to other mod-
els of chronic antigen exposure. Finally, these hypotheses must be
tested in human immune responses, where a better understand-
ing of T-cell metabolism might lead to enhanced vaccine strate-
gies, improved anti-cancer responses, novel interventions against
autoimmunity, and better post-transplant immunotherapy.
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